NOVOSEVEN Powder and solvent for solution for injection Ref.[9448] Active ingredients: Coagulation factor VIIa

Source: European Medicines Agency (EU)  Revision Year: 2019  Publisher: Novo Nordisk A/S, Novo Allé, DK-2880, Bagsværd, Denmark

Product name and form

NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection.
NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection.
NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection.
NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection.

Pharmaceutical Form

Powder and solvent for solution for injection.

White lyophilised powder.

Solvent: clear colourless solution. The reconstituted solution has a pH of approximately 6.0.

Qualitative and quantitative composition

NovoSeven 1 mg (50 KIU): NovoSeven is presented as powder and solvent for solution for injection containing 1 mg eptacog alfa (activated) per vial (corresponds to 50 KIU/vial).

NovoSeven 2 mg (100 KIU): NovoSeven is presented as powder and solvent for solution for injection containing 2 mg eptacog alfa (activated) per vial (corresponds to 100 KIU/vial).

NovoSeven 5 mg (250 KIU): NovoSeven is presented as powder and solvent for solution for injection containing 5 mg eptacog alfa (activated) per vial (corresponds to 250 KIU/vial).

NovoSeven 8 mg (400 KIU): NovoSeven is presented as powder and solvent for solution for injection containing 8 mg eptacog alfa (activated) per vial (corresponds to 400 KIU/vial).

1 KIU equals 1,000 IU (International Units).

Eptacog alfa (activated) is recombinant coagulation factor VIIa (rFVIIa) with a molecular mass of approximately 50,000 Daltons produced in baby hamster kidney cells (BHK Cells) by recombinant DNA technology.

After reconstitution, the product contains 1 mg/ml eptacog alfa (activated) when reconstituted with solvent.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Coagulation factor VIIa

Pharmacological doses of rFVIIa activate factor X directly on the surface of activated platelets, localized to the site of injury, independently of tissue factor. This results in the conversion of prothrombin into large amounts of thrombin independently of tissue factor.

List of Excipients

Powder:

Sodium chloride
Calcium chloride dihydrate
Glycylglycine
Polysorbate 80
Mannitol
Sucrose
Methionine
Hydrochloric acid (for pH-adjustment)
Sodium hydroxide (for pH-adjustment)

Solvent:

Histidine
Hydrochloric acid (for pH-adjustment)
Sodium hydroxide (for pH-adjustment)
Water for injections

Pack sizes and marketing

The solvent of NovoSeven is provided in either a vial or in a pre-filled syringe. Not all presentations may be marketed.

The NovoSeven 1 mg (50 KIU)/NovoSeven 2 mg (100 KIU) package contains either:

  • 1 vial (2 ml) with white powder for solution for injection
  • 1 vial (2 ml) with solvent for reconstitution

or

  • 1 vial (2 ml) with white powder for solution for injection
  • 1 pre-filled syringe (3 ml) with solvent for reconstitution
  • 1 plunger rod
  • 1 vial adapter, with an integrated particle filter with a pore size of 25 micrometer.

The NovoSeven 5 mg (250 KIU)/NovoSeven 8 mg (400 KIU) package contains either:

  • 1 vial (12 ml) with white powder for solution for injection
  • 1 vial (12 ml) with solvent for reconstitution

or

  • 1 vial (12 ml) with white powder for solution for injection
  • 1 pre-filled syringe (10 ml) with solvent for reconstitution
  • 1 plunger rod
  • 1 vial adapter, with an integrated particle filter with a pore size of 25 micrometer.

Vial: Type I glass vial closed with a chlorobutyl rubber stopper, covered with an aluminium cap. The closed vial is equipped with a polypropylene tamper-evident snap-off cap.

Pre-filled syringe: Type I glass barrel with a polypropylene backstop and bromobutyl rubber plunger. The syringe cap consists of bromobutyl rubber and polypropylene tamper evident seal.

Plunger rod: made of polypropylene.

Marketing authorization holder

Novo Nordisk A/S, Novo Allé, DK-2880, Bagsværd, Denmark

Marketing authorization dates and numbers

NovoSeven 1 mg (50 KIU):

EU/1/96/006/004
EU/1/96/006/008

NovoSeven 2 mg (100 KIU):

EU/1/96/006/005
EU/1/96/006/009

NovoSeven 5 mg (250 KIU):

EU/1/96/006/006
EU/1/96/006/010

NovoSeven 8 mg (400 KIU):

EU/1/96/006/007
EU/1/96/006/011

Date of first authorisation: 23 February 1996
Date of latest renewal: 23 February 2006

Drugs

Drug Countries
NOVOSEVEN Austria, Brazil, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.